Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
73 hedge funds and large institutions have $103M invested in Sierra Oncology, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 29 increasing their positions, 3 reducing their positions, and 6 closing their positions.
867% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 3
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
43% more funds holding
Funds holding: 51 → 73 (+22)
11% less capital invested
Capital invested by funds: $115M → $103M (-$12.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.82M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$7.2M |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
+$6.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.96M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.83M |
| 2 |
AC
AWH Capital
Dallas,
Texas
|
-$1.37M |
| 3 |
EP
Eversept Partners
New York
|
-$250K |
| 4 |
Two Sigma Investments
New York
|
-$245K |
| 5 |
JG
Jefferies Group
New York
|
-$224K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$144K | -967 | Closed |
|
|
TAM
77
Tocqueville Asset Management
New York
| – | -$47K | -313 | Closed |
|
78
Two Sigma Advisers
New York
| – | -$43K | -290 | Closed |
|
79
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$10K | -65 | Closed |
|
SRRA Hedge Fund Activity: Q1 2018 in Review
73 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2018, worth a combined $103M — down 11% from $115M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new SRRA positions and 6 closed out — a net gain of 22 holders — while 29 added to existing stakes and 3 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $8.82M. The largest seller was OrbiMed, cutting an estimated $2.83M.
- 73 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2018, up from 51 in Q4 2017.
- Funds reported $103M of Sierra Oncology, Inc. Common Stock stock for Q1 2018, down 11% quarter-over-quarter.
- 28 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2018 and 6 closed out, a net change of +22 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2018 was Great Point Partners, an estimated $8.82M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2018 was OrbiMed, an estimated $2.83M sold.
Based on aggregated 13F filings for Q1 2018.